In this respect, the automatized IHC procedure with the SP44 anti-MET antibody (by Ventana Medical Systems, Inc., Roche Diagnostics A/S, Hvidovre, Denmark) that we used for our five reported cases is the one routinely used for predictive diagnostics in most pathology departments and in most clinical trials employing MET-TKIs for EGFRm+ NSCLC patients with acquired MET amplification/overexpression [22,62]. Here, MET is linked to non-small cell lung carcinoma.